EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the ninth of December, 2015 by and between Jounce Therapeutics, Inc. (the “Company”), and Anna L. Barry (the “Executive”). Except with respect to the Restrictive Covenants (as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the letter agreement between the Employee and the Employer dated November 26, 2013 and Employment Agreement dated October 7, 2015 (the “Former Employment Agreements”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Jounce Therapeutics, Inc. (the “Company”), and Elizabeth G. Trehu (the “Executive”). The effective date of this Agreement shall be first date of actual employment with the Company. In the event that the Executive does not commence actual employment with the Company, this Agreement shall become null and void and of no further force or effect.
JOUNCE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of April 17, 2015, by and among Jounce Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
ContractExclusive License Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
MASTER RESEARCH AND COLLABORATION AGREEMENT by and among JOUNCE THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE RIVOT LLC Dated as of July 18, 2016Master Research and Collaboration Agreement • October 12th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This CELGENE LEAD CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “Celgene Lead Co-Co Agreement”) is entered into and made effective as of [·], 20 (the “Execution Date”) by and among Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Celgene Lead Co-Co Agreement in the United States, and Celgene RIVOT LLC, a Delaware limited liability company (“Celgene RIVOT”), with respect to all rights and obligations under this Celgene Lead Co-Co Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, “Celgene”). Celgene and Jounce are each referred to herein as a “Party” or, collectively, as the “Parties.”
